Q4 2018 Earnings Forecast for Heska Corp Issued By B. Riley (HSKA)

Heska Corp (NASDAQ:HSKA) – Investment analysts at B. Riley cut their Q4 2018 earnings per share estimates for shares of Heska in a research note issued on Wednesday, November 7th. B. Riley analyst K. Anderson now expects that the medical research company will post earnings of $0.71 per share for the quarter, down from their previous forecast of $0.77. B. Riley also issued estimates for Heska’s Q2 2019 earnings at $0.36 EPS, Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.68 EPS and FY2019 earnings at $1.96 EPS.

HSKA has been the subject of a number of other research reports. ValuEngine downgraded shares of Heska from a “buy” rating to a “hold” rating in a report on Monday, July 30th. BidaskClub downgraded shares of Heska from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Investment Research upgraded shares of Heska from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 18th. Benchmark began coverage on shares of Heska in a report on Thursday, July 19th. They issued a “buy” rating and a $120.00 price target for the company. Finally, TheStreet downgraded shares of Heska from a “b” rating to a “c+” rating in a report on Monday, August 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $107.50.

Shares of HSKA opened at $102.99 on Thursday. The stock has a market capitalization of $751.73 million, a PE ratio of 62.27 and a beta of 0.73. Heska has a 52-week low of $56.59 and a 52-week high of $114.50.

Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 EPS for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.11. The company had revenue of $30.96 million during the quarter, compared to the consensus estimate of $31.14 million. Heska had a net margin of 1.01% and a return on equity of 11.48%.

In related news, EVP Steve Asakowicz sold 8,000 shares of the stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $101.03, for a total value of $808,240.00. Following the sale, the executive vice president now directly owns 9,600 shares of the company’s stock, valued at approximately $969,888. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Steven M. Eyl sold 33,351 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $98.49, for a total transaction of $3,284,739.99. Following the completion of the sale, the executive vice president now directly owns 15,401 shares in the company, valued at $1,516,844.49. The disclosure for this sale can be found here. Insiders sold a total of 56,777 shares of company stock valued at $5,751,062 in the last quarter. Insiders own 14.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC acquired a new stake in Heska in the 2nd quarter valued at about $162,000. SG Americas Securities LLC acquired a new stake in Heska in the 2nd quarter valued at about $191,000. Paloma Partners Management Co acquired a new stake in Heska in the 2nd quarter valued at about $228,000. Macquarie Group Ltd. acquired a new stake in Heska in the 2nd quarter valued at about $234,000. Finally, Raymond James Trust N.A. acquired a new stake in Heska in the 2nd quarter valued at about $240,000. 88.63% of the stock is currently owned by hedge funds and other institutional investors.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

See Also: What is a capital gain?

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply